The safety and interpretability of skin tests with omalizumab.

نویسندگان

  • Phillip Lieberman
  • Abdelkader Rahmaoui
  • Dennis A Wong
چکیده

other laboratory values were unremarkable. A biopsy specimen was not taken. The patient was treated with 0.05% topical desonide lotion for the rash, the antihistamines hydroxyzine and levocetirizine for the pruritus, and empirical antibiotics for possible systemic infection. On day 4, his fever had subsided completely and all blood culture results were negative. On day 6, generalized cutaneous desquamation occurred with marked resolution of his erythema and pustules. AGEP is characterized by a sudden onset of fever and widespread numerous nonfollicular sterile pustules and has a benign, self-limiting course.1 Although most cases of AGEP (!90%) have been associated with drugs, in particular antibiotics, its origin is variable, and it may be triggered by viral infection, hypersensitivity to mercury, or spider bites. Several case reports have described patients with AGEP induced by contrast media, including 2 patients with delayed, generalized, and protracted cutaneous reactions compatible with AGEP after contrast medium administration,4 1 patient with contrast-induced AGEP,5 and 1 patient who developed a pruritic pustular eruption on 2 separate occasions after administration of a nonionic contrast medium.6 The main histopathologic findings in most patients with AGEP include spongiform superficial pustules, papillary edema, polymorphonuclear cells with some perivascular eosinophils, and leukocytoclastic vasculitis with fibrinoid deposits. Our patient had the characteristic morphologic features and course of AGEP, except that histologic features could not be identified because no biopsy specimen was obtained. To our knowledge, this is the first case of AGEP induced by contrast media ever reported in Korea. Physicians should bear in mind that AGEP can be induced by radiocontrast media.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria. Several randomised controlled trials have investigated the safety, tolerability, and efficacy of omalizumab for chronic urticaria. The safety of omalizum...

متن کامل

Benefits of omalizumab on anxiety and depression in patients with severe asthma

Background: Asthma is one of the most common chronic diseases and may cause psychiatric disorders affecting the patients’ quality of life. In our study, we evaluated the effect of omalizumab treatment on anxiety disorder and depression using Beck Depression Scale (BDS) and State Trait Anxiety Inventory (STAI). Methods: Anxiety level was determined with STAI, whereas depression level was ...

متن کامل

Omalizumab: what benefits should we expect?

Chronic spontaneous urticaria (CSU) is a skin disease characterised by wheal appearance, swelling, itching, and painful skin. Omalizumab has been used for CSU treatment demonstrating good efficacy. To investigate the efficacy and safety of omalizumab treatment in CSU patients in real-life practice. A retrospective analysis was performed on 38 patients suffering from CSU who received 300 mg of o...

متن کامل

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI+) and IgE-positive (IgE+) dermal c...

متن کامل

Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A spec...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

دوره 105 6  شماره 

صفحات  -

تاریخ انتشار 2010